Biora Therapeutics, Inc.

OTCPK:BIOR.Q Stock Report

Market Cap: US$597.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biora Therapeutics Management

Management criteria checks 3/4

Biora Therapeutics' CEO is Adi Mohanty, appointed in Nov 2021, has a tenure of 3.5 years. total yearly compensation is $3.14M, comprised of 18.3% salary and 81.7% bonuses, including company stock and options. directly owns 0.52% of the company’s shares, worth $3.10K. The average tenure of the management team and the board of directors is 3.3 years and 3.9 years respectively.

Key information

Adi Mohanty

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage18.29%
CEO tenure3.5yrs
CEO ownership0.5%
Management average tenure3.3yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 13

Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists

Biora Therapeutics (NASDAQ:BIOR) said on Tuesday the United States Patent and Trademark Office had issued a patent related to the company’s technologies for oral, systemic delivery of biologics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The patent is for methods for using an ingestible device to treat a disease or condition in a patient using jet delivery of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist formulation to the small intestine. GLP-1 receptor agonists are a class of drug approved for type 2 diabetes and weight loss.
Seeking Alpha • Aug 17

Biora Therapeutics: Checking In On The Transformation

Today, we take our first look at the rebranded/refocused Biora Therapeutics in 2022. When we last looked at this company, it was still transitioning from being a genetic testing company to being a developmental drug company. How is the transformation working out to date?  An investment analysis follows in the paragraphs below. Everyone thinks of changing the world, but no one thinks of changing himself." - Leo Tolstoy Today, we put Biora Therapeutics (BIOR) in the spotlight for the first time this year. When we last looked at this entity in the fourth quarter of last year, it was still transitioning from being an entity called Progenity (PROG). The company was in the middle of transforming from its focus as a genetic testing company to being a company focused on developing its drug candidates. Second quarter results just hit the wires this week. Therefore, it seems an opportune time to peak back in on this small cap concern and check in on how its transformation is proceeding. An analysis follows below. Seeking Alpha Company Overview: August Company Presentation The refocused Biora Therapeutics is still based in San Diego. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the GI tract to enhance the treatment of inflammatory bowel diseases. Leadership believe this approach has plenty of potential targets, including holding great promise to more effectively treat Ulcerative Colitis, a large indication. It also is targeting IBD. According to management on its last earnings conference call. Annual global sales for UC drugs are estimated to be approximately $7 billion and the inflammatory bowel disease or IBD space overall is about $19 billion globally. " August Company Presentation August Company Presentation Here is the current development plan for the most advanced candidate in this developmental area, PGN - 600, which is combination of Biora's device and their proprietary formulation of tofacitinib. August Company Presentation The company is also focused on an oral delivery approach via ingestible capsules as an alternative to intramuscular injectable vaccines. This method could eventually see use for proteins as well as monoclonal antibodies. August Company Presentation The replacement of needle injection via an easy to take oral capsule could yield more effective results in a variety of disease areas. The company has a research collaboration with Ionis Pharmaceuticals (IONS) in these initial efforts. Preclinical activities should run into the third quarter of 2023, and are scheduled to start early stage clinical activities by the end of that year. The company estimates the area of the diabetes market it is targeting to be well over $20 billion by 2025. August Company Presentation Management believes the management of diabetes could be vastly improved to name one large target area. August Company Presentation With two core developmental focus areas, the company has numerous candidates in the pipeline. The company's portfolio has numerous patents around the company's intellectual property. That said, its candidates all in the very early stages of the long developmental lifecycle as can be seen above. August Company Presentation
Seeking Alpha • Aug 10

Biora rallies 30%, highest since November on data for drug delivery device

Biora Therapeutics (NASDAQ:BIOR), a biotech focused on oral biotherapeutics, surged ~30% on Wednesday to record the highest intraday gain since November after the company announced promising topline data from a study for its targeted therapeutics platform. The recently completed PM-602 was designed to evaluate the Drug Delivery System Capsule (DDS) in patients with ulcerative colitis in a fasted state. According to the data, the device was well tolerated and performed as expected in all UC patients after a single oral ingestion. Accurately identifying the entry into the colon, the device released a saline solution payload that included radioisotopes, leading to distribution across the entire colon in all seven patients. Biora (BIOR) plans to release further information on the study after completing the analysis and intends to submit data for publication. “These human studies are key steps in advancing toward our PGN-600 clinical program, and they also demonstrate the potential of the platform for localized delivery of other drugs,” Chief Executive Adi Mohanty noted. Biora (BIOR) was previously identified as Progenity.

CEO Compensation Analysis

How has Adi Mohanty's remuneration changed compared to Biora Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$111m

Dec 31 2023US$3mUS$574k

-US$124m

Sep 30 2023n/an/a

-US$122m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$4mUS$550k

-US$49m

Sep 30 2022n/an/a

-US$118m

Jun 30 2022n/an/a

-US$140m

Mar 31 2022n/an/a

-US$176m

Dec 31 2021US$10mUS$63k

-US$179m

Compensation vs Market: Adi's total compensation ($USD3.14M) is above average for companies of similar size in the US market ($USD651.56K).

Compensation vs Earnings: Adi's compensation has been consistent with company performance over the past year.

CEO

Adi Mohanty (57 yo)

3.5yrs
Tenure
US$3,139,017
Compensation

Mr. Aditya P. Mohanty, also known as Adi,M.B.A. serves as Chief Executive Officer and Director at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since November 8, 2021. Mr. Mohanty founded En...

Leadership Team

NamePositionTenureCompensationOwnership
Aditya Mohanty
CEO & Director3.5yrsUS$3.14m0.52%
$ 3.1k
Clarke Neumann
Senior VP10.7yrsUS$1.53m0.18%
$ 1.1k
Kevin Howe
Senior VP of Strategic Operationsno datano datano data
Paul Shabram
Head of Technical Operations3.1yrsno datano data
James Knight
Head of Business Development1.3yrsno datano data
3.3yrs
Average Tenure

Experienced Management: BIOR.Q's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Aditya Mohanty
CEO & Director3.5yrsUS$3.14m0.52%
$ 3.1k
Brian Gordon Feagan
Member of Inflammatory Bowel Disease Clinical Advisory Boardno datano datano data
Brian Kotzin
Independent Director5.9yrsUS$185.11k0.041%
$ 245.8
Geert D'Haens
Member of Inflammatory Bowel Disease Clinical Advisory Board3.9yrsno datano data
Bruce Sands
Chairman of Inflammatory Bowel Disease Clinical Advisory Board3.9yrsno datano data
Jeffrey Alter
Independent Chairman6.3yrsUS$208.11k0.043%
$ 256.5
Lynne Powell
Independent Director6.3yrsUS$163.11k0.041%
$ 245.7
Severine Vermeire
Member of Inflammatory Bowel Disease Clinical Advisory Board3.9yrsno datano data
Jill Howe
Independent Director3.5yrsUS$180.11k0.040%
$ 241.1
3.9yrs
Average Tenure
57yo
Average Age

Experienced Board: BIOR.Q's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 07:33
End of Day Share Price 2025/05/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biora Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Steven MahPiper Sandler Companies
Andrew CooperRaymond James & Associates